MiMedx Group (MDXG) Peer Comparison
$3.31
$0.03
(0.91%)
As on 06-Nov-2026 16:00EST
Market cap
$483 Mln
Revenue (TTM)
$304 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Edit
| MiMedx Group (MDXG) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
483 | 18,269 | 16,976 | 11,246 | 5,467 |
Revenue ($ Mln) |
304 | 2,838 | 2,497 | 102 | 1,156 |
Net Profit ($ Mln) |
-19.19 | 517.83 | 885.14 | -349.47 | -105.97 |
Net Margin (%) |
-6.32 | 18.24 | 35.45 | -341.87 | -9.17 |
RoE (%) |
-8.46 | 87.53 | 46.96 | -22.16 | -- |
Price to Earnings |
-- | 36.26 | 20.83 | -- | -- |
Price-To-Book |
2.27 | 30.39 | 9.26 | 6.79 | 1,743.27 |
Income Statement ($ Mln)
| MiMedx Group (MDXG) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
303.73 | 2,838.39 | 2,496.86 | 102.23 | 1,155.55 |
|
Cost of Revenue
|
68.99 | 2,011.22 | 93.32 | -74.16 | 87.91 |
|
Gross Profit
|
345.62 | 760.62 | 2,236.43 | 39.20 | 1,658.90 |
|
Operating Expenses
|
259.46 | 220.03 | 1,400.14 | 583.29 | 929.29 |
|
Operating Profit (EBIT)
|
-25.14 | 607.14 | 1,003.39 | -404.89 | 138.35 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-22.38 | 626.99 | 1,065.84 | -349.70 | -85.09 |
|
Provision for Tax
|
-3.19 | 109.17 | 180.70 | 0.00 | 20.88 |
|
Profit after Tax (Net Income)
|
-19.19 | 517.83 | 885.14 | -349.47 | -105.97 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| MiMedx Group (MDXG) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
211.08 | 584.94 | 1,833.83 | 1,614.53 | -191.21 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
10.44 | 221.56 | 267.78 | 63.02 | 2,622.85 |
|
Current Liabilities
|
43.03 | 1,496.10 | 411.88 | 89.72 | 776.08 |
|
Total Liabilities
|
342.65 | 1,975.47 | 2,844.42 | 1,742.81 | 2,898.77 |
Assets ($ Mln)
| MiMedx Group (MDXG) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
77.32 | 1,057.60 | 1,191.87 | 768.68 | 669.93 |
|
Current Assets
|
187.23 | 1,245.00 | 1,321.62 | 998.59 | 2,537.78 |
|
Total Assets
|
342.65 | 1,975.47 | 2,844.42 | 1,742.81 | 2,898.77 |
|
Total Debt*
|
0.00 | 146.04 | 162.20 | 76.60 | 636.03 |
|
Net Current Assets
|
144.20 | -251.10 | 909.75 | 908.87 | 0.00 |
Cashflow ($ Mln)
| MiMedx Group (MDXG) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
74.00 | 713.22 | 884.27 | -232.89 | 711.20 |
|
Cash Flow from Investing Activities
|
-6.89 | -31.14 | 350.44 | -521.06 | -861.98 |
|
Cash from Financing Activities
|
-5.41 | -860.39 | -969.59 | 990.71 | 331.09 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| MiMedx Group (MDXG) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
19.55 | 57.43 | 32.82 | -24.09 | 35.24 |
|
ROE (%)
|
-8.46 | 87.53 | 46.96 | -22.16 | -104.75 |
|
ROA (%)
|
-5.61 | 15.15 | 28.91 | -23.06 | -2.29 |
|
EBIT Margin (%)
|
-7.67 | 21.70 | 42.02 | -341.82 | 9.82 |
|
Net Margin (%)
|
-6.32 | 18.24 | 35.45 | -341.87 | -9.17 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| MiMedx Group (MDXG) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-22.80 | 20.35 | 9.12 | 133.74 | -35.05 |
|
EBIT Growth (%)
|
-140.62 | 18.61 | 23.13 | -18.50 | -87.09 |
|
Net Profit Growth (%)
|
-147.01 | 19.59 | 30.57 | -18.42 | -114.10 |
|
EPS Growth (%)
|
-148.20 | 28.06 | 38.78 | -2.42 | -116.63 |
|
Book Value Growth (%)
|
-9.33 | 108.60 | -7.57 | 48.81 | -28.11 |
Valuation Ratios
| MiMedx Group (MDXG) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
20.87 | 36.06 | 15.79 | -21.09 | 8.98 |
|
Price / Book Value
|
3.95 | 35.44 | 5.72 | 4.16 | -29.85 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
10.49 | 27.88 | 12.44 | -19.14 | 7.76 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| MiMedx Group (MDXG) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.00 | 0.01 | -0.07 |
|
Current Ratio
|
4.35 | 0.83 | 3.21 | 11.13 | 3.27 |
|
Quick Ratio
|
3.84 | 0.83 | 3.14 | 11.13 | 3.13 |
|
Interest Coverage
|
-21.00 | -- | -- | -1,279.94 | 0.57 |
Operating Efficiency Ratios
| MiMedx Group (MDXG) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
12.27 | 15.77 | 13.16 | 0.00 | 20.60 |
|
Asset Turnover
|
0.89 | 0.83 | 0.82 | 0.07 | 0.25 |
|
Receivable days
|
57.38 | 50.42 | 43.48 | 8.82 | 35.90 |
|
Inventory Days
|
122.93 | -- | 96.17 | -- | 261.74 |
|
Payable days
|
54.87 | 6.26 | 147.97 | -- | 159.73 |
|
Cash Conversion Cycle
|
125.44 | -- | -8.32 | -- | 137.90 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
